FDA agrees to review Enzychem’s IND for COVID-19 trial – Global New Drug Development Company |

About us
Our Science
- EC-18 Technology Platform
- Potential Therapeutic Indications
  - CRIOM
  - CIN
  - ARS
  - COVID-19
  - ICI Combination
  - NASH
Pipeline
IR/PR
- PR
- IR
  - IR Documents
Partner & Collaboration
Contact

About us
Our Science
- EC-18 Technology Platform
- Potential Therapeutic Indications
  - CRIOM
  - CIN
  - ARS
  - COVID-19
  - ICI Combination
  - NASH
Pipeline
IR/PR
- PR
- IR
  - IR Documents
Partner & Collaboration
Contact

About us
Our Science
- EC-18 Technology Platform
- Potential Therapeutic Indications
  - CRIOM
  - CIN
  - ARS
  - COVID-19
  - ICI Combination
  - NASH
Pipeline
IR/PR
- PR
- IR
  - IR Documents
Partner & Collaboration
Contact

News

August 13, 2020

Enzychem in the News

FDA agrees to review Enzychem’s IND for COVID-19 trial

Press Release
Enzychem in the News
Publications

United States Office

1 Bridge Plaza North, STE 710, Fort Lee,
NJ U.S.A. 07024

Corporate Headquarters

10F, aT Center, 27 Gangnamdae-ro Seocho-gu,
Seoul, South Korea

R&D Center

13F, Gyeonggi Bio Center, 147,Gwanggyo-ro, Yeongtong-gu, Suwon-si,
Gyeonggi-do, South Korea

FOr More Information

info@enzychem.com

+1 856-415-6609

Privacy Policy
Terms & Conditions
Site map

CopyRight 2021 Enzychem Lifesciences Corporation, All Right Reserved.